KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer

Opinion
Video

Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Erika P. Hamilton, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Erika P. Hamilton, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Erika P. Hamilton, MD, presenting slides
Sandra M. Swain, MD, FACP, FASCO, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Related Content